MGMT and neoplasm: Although at first glance these findings suggest MGMT methylation as a marker of better response to treatment, we propose a more fundamental difference and hypothesize a potential intrinsic difference in the tumour biology related to the MGMT promoter methylation status that confers a better prognosis per se, irrespective of the treatment offered to the patient.